Objective To assess surgical morbidity and mortality of maximal effort cytoreductive surgery for disseminated epithelial ovarian cancer (EOC) in a UK tertiary center. Methods/materials A monocentric prospective analysis of surgical morbidity and mortality was performed for all consecutive EOC patients who underwent extensive cytoreductive surgery between 01/2013 and 12/2014. Surgical complexity was assessed by the Mayo clinic surgical complexity score (SCS). Only patients with high SCS C5 were included in the analysis. Results We evaluated 118 stage IIIC/IV patients, with a median age of 63 years (range 19-91); 47.5 % had ascites and 29 % a pleural effusion. Median duration of surgery was 247 min (range 100-540 min). Median surgical complexity score was 10 (range 5-15) consisting of bowel resection (71 %), stoma formation (13.6 %), diaphragmatic stripping/resection (67 %), liver/liver capsule resection (39 %), splenectomy (20 %), resection stomach/lesser sac (26.3 %), pleurectomy (17 %), coeliac trunk/subdiaphragmatic lymphadenectomy (8 %). Total macroscopic tumor clearance rate was 89 %. Major surgical complication rate was 18.6 % (n = 22), with a 28-day and 3-month mortality of 1.7 and 3.4 %, respectively. The anastomotic leak rate was 0.8 %; fistula/bowel perforation 3.4 %; thromboembolism 3.4 % and reoperation 4.2 %. Median intensive care unit and hospital stay were 1.7 (range 0-104) and 8 days (range 4-118), respectively. Four patients (3.3 %) failed to receive chemotherapy within the first 8 postoperative weeks. Conclusions Maximal effort cytoreductive surgery for EOC is feasible within a UK setting with acceptable morbidity, low intestinal stoma rates and without clinically relevant delays to postoperative chemotherapy. Careful patient selection, and coordinated multidisciplinary effort appear to be the key for good outcome. Future evaluations should include quality of life analyses.
Introduction
Epithelial ovarian cancer (EOC) is the 4th most common cancer in women and the most fatal gynecological malignancy [1] . Surgery remains one of the main therapeutic modalities, although controversy exists around the extent and limitations of cytoreductive procedures, the optimum timing of surgery and the selection of ideal surgical candidates. These issues make the management of this complex disease challenging, and have resulted in wide variations in practice nationally and internationally [2] [3] [4] [5] . Comparisons of EOC patients' mortality and treatment in Europe within the EUROCARE 5 study have identified large survival differences among the European countries, with a 5-year relative survival ranging from 31 % in Ireland and the United Kingdom (lowest) to 41 % in Northern Europe (highest) and a European average of 38 %, across all stages [3] . Assuming that intrinsic tumor biology of EOC is not worse in some countries than others, differences in survival are probably attributed to variations in management, variability in healthcare and institutional resources and ultimately perhaps the entire philosophy of the overall therapeutic approach, both systemic and surgical. Barton et al. from the Royal Marsden Institute in the UK, demonstrated this by showing, through an anonymized questionnaire survey among UK consultant gynecological oncologists, that the surgical goal of ovarian debulking surgery in many UK cancer centers is not complete cytoreduction [6] . This was reflected in short operating times, and highly variable rates of bowel surgery, upper abdominal resections and lymphadenectomies; all surrogate markers of surgical endeavor. The authors concluded that this is likely to directly contribute to the relatively poor outcomes in UK EOC patients [6] . Opponents of maximal effort cytoreductive surgery argue that increased surgical morbidity resulting in a negative impact on quality of life as well as exhaustion of financial and institutional resources are detrimental to patient care. Nevertheless, increasing evidence suggests that specialization and expertise leads to higher tumor resection rates and hence potentially improved survival without equivalent increase in complication rates or length of hospitalization [7] .
The present work represents the evaluation of an attempt at maximization of surgical tumor clearance in patients with peritoneal disseminated EOC within the UK system; these patients underwent multivisceral cytoreducion for total macroscopic tumor clearance. We evaluated theater and hospitalization times, surgical morbidity and mortality, delays in chemotherapy and anesthetic and peri-operative care issues.
Materials and methods
A retrospective evaluation of a prospectively gathered clinical database was performed to assess the intraoperative tumor dissemination pattern, surgical outcome and morbidity as well as the anesthetic and peri-operative care for all consecutive patients who underwent extensive cytoreductive surgical procedures for advanced primary or relapsed EOC in our center, between January 2013 and December 2014. Surgical complexity scores (SCS) were calculated using the Mayo Clinic complexity scoring system [8] . Only patients with advanced FIGO-stage IIIC/IV disease that underwent surgery with a SCS C5 were included [9] . Patients with tumors of non-epithelial origin and those receiving surgery with palliative and not cytoreductive aim, such as relief of bowel obstruction or perforation, were excluded. Under current UK research governance arrangements, this analysis of routinely captured clinical data is classified as a service evaluation and is exempt from the requirement for research ethical review.
All operations were performed through a midline laparotomy by a team of gynecological and, when necessary, hepatobiliary surgeons to achieve total macroscopic tumor clearance. No systematic pelvic and para-aortic lymph node dissection was performed routinely in the absence of bulky lymph nodes (defined as[1 cm). Patients with large volume ascites and/or pleural effusions, and those with major comorbidities and/or advanced age were routinely admitted to the intensive care unit for postoperative care.
In every patient, the intraoperative tumor dissemination pattern was assessed prospectively via a validated descriptive system (IMO: ''Intraoperative Mapping of Ovarian Cancer'' [10] [11] [12] ), specifically developed for ovarian neoplasms. Three ''IMO-levels'' divide the abdomen into three spaces: lower (level-1), middle (level-2) and upper (level-3) abdomen (Fig. 1) . Nine ''IMO-fields'', three at each level, provide a sub-classification of the peritoneal cavity that provides a more precise documentation of the tumor dissemination pattern.
Indications for surgery
The management of all patients and the indications for surgery were discussed within a multidisciplinary team (MDT), consisting of five specialized gynecological oncology surgeons among medical and clinical oncologists, gynae-radiologists, gynae-pathologists, and clinical nurse specialists. Patients with primary advanced EOC were considered for primary debulking surgery unless they had unresectable parenchymal distant and/or extra-abdominal metastases and/or had a poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status C3). Primarily one to two gynecological oncology surgeons would perform the operations together with a hepatobiliary surgeon if needed.
Patients who were referred for consideration of interval debulking, having received neoadjuvant chemotherapy in other centers, were deemed suitable for surgery as long as they showed response to platinum or had stable disease according to RECIST criteria [13] , and had a good performance status. In cases with pleural effusions, the pleural cavity was evaluated via the diaphragm, to ensure that no diffuse unresectable pleural carcinosis was present.
Patients with relapsed disease were considered for cytoreductive surgery if the recurrence occurred in a platinum sensitive time frame, they did not have progressively re-accumulating ascites or pleural effusions, did not have unresectable distant metastatic lesions and were fit for surgery.
Statistics
Statistical analysis was performed using SPSS statistical software, version 16.0 (SPSS Inc., 233 S. Wacker Drive, Chicago, USA). Estimates of survival were calculated using the Kaplan-Meier method. All parameters are expressed as median and range. The follow-up and survival times were calculated starting on the day of surgery. All percentages given are in relation to the entire cohort of patients (n = 118).
Results
We included 118 consecutive EOC patients. Median age was 63 years (range 19-91). Seventeen patients (14.4 %) were C75 years old. Median body mass index was 25 kg/ m 2 (range 11-46). The majority of patients were stage IIIC (69.5 %) and most were of high-grade serous histology (89 %). Almost half of the patients (n = 56; 47.5 %) had more than 500 ml of ascites. Nineteen patients (16.1 %) had unilateral and 15 patients (12.7 %) bilateral pleural effusions pre-operatively. The timing and type of the surgery was as follows: 56.8 % (n = 67) upfront/primary debulking; 22.9 % (n = 27) interval debulking; 18.6 % (n = 22) secondary debulking and 1.7 % (n = 2) tertiary debulking. For patients who underwent interval debulking surgery, the median number of neoadjuvant chemotherapy cycles was 3 (range 2-6). Detailed patient and tumor-related characteristics, and ECOG status [14] , are presented in Table 1 .
Tumor dissemination patterns and surgical procedures
The median number of IMO fields involved with tumor was 9 (range 2-9); the majority of patients (n = 100; 84.7 %) had tumor involvement in more than 7 IMO fields (see Fig. 1 ).
In 105 (89 %) patients a complete macroscopic tumor resection was achieved. The most common sites of residual disease were middle (10.2 %) and upper abdomen (9.3 %) compared to only 1.7 % residual disease in pelvis ( Table 1 ). The median complexity score was 10 (range 5-15), with the majority of patients (n = 86; 73 %) undergoing surgery with a SCS C8. The median complexity score for patients at the initial presentation of their disease was 9.5 (range 5-18), and at relapse 8 (range 4-13). Median duration of surgery was 247 min (range 100-540), with a duration of 4 h or less in 44 % of cases.
The surgical procedures that were performed outside of the ''standard'' total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy are presented in Table 2 . Hepatic surgery (39.0 %) consisted of multiple debulking from liver capsule (n = 43) or minor resection (\3 segments, n = 3). Sixty-five patients (55.1 %) received one or more primary bowel anastomosis, with 19 patients (16.1 %) having [1 bowel anastomoses. The most common type of anastomosis was end-to-end rectosigmoid anastomosis (n = 45; 39 %), followed by side-to-side small to large bowel anastomosis (n = 14; 11.9 %). No protective stoma were performed in such cases. Sixteen patients (13.6 %) received a primary terminal intestinal stoma: 2 (1.7 %) received an ileostomy and 14 (11.8 %) a colostomy. All stomas were intended to be reversible. Median postoperative hospital stay for all patients was 8 days (range 4-118).
Surgical morbidity and mortality and ability to receive postoperative chemotherapy
The 28-day surgical mortality rate was 1.7 % (n = 2) for the patients at their initial presentation of their disease and 0 for the relapsed patients. One patient died of fulminant sepsis with no primary focus identified and one patient died from fulminant hepatic failure, both on the third postoperative day. The patient with hepatic failure had not received any major segmental liver resection and the CT after onset of symptoms showed no evidence of portal or hepatic vein thrombosis or infarct, no biliary leak or haematoma/abscess. Two further patients died within the first 3 months due to rapid and platinum refractory disease progression with liver and lung metastases (3 months mortality 3.4 %). The 3 months mortality of the relapsed patients alone was 0. Twenty-two patients (18.6 %) suffered at least one major surgical complication during the first 28 postoperative days (Table 2 ). If we divide them according to the stage of the disease; then 22 % of the patients at their primary presentation experienced a major morbidity versus only 4 % of the relapsed patients. The one patient with anastomotic leak of a rectosigmoid anastomosis was managed conservatively and did not require reoperation. The patient who developed a pelvic abscess was successfully treated with CT-guided drainage for 5 days and did not require further operative intervention. None of the patients with persistent lymphorrhea needed re-operation; they were treated with serial abdominal drains and octreotide, with the lymphorrhea resolving in a median time of 3.2 weeks. Four patients (3.4 %) required re-operation for: aortoduodenal fistula (n = 1) 21 days postoperatively; postoperative hemorrhage (n = 1) 2 days after interval debulking surgery, and bowel perforation (n = 2), unrelated to a bowel anastomosis, but rather as a consequence of extensive peritoneal stripping. None of those patients who required re-operation died, and were eventually discharged home. Readmission rate was 10 % (n = 12) for: spontaneously resolving vaginal discharge (n = 1); lymphorrhea/lymphocyst (n = 3); diarrhea (n = 1), pre-existing hyponatraemia (n = 1), fistula formation (n = 1), infection/abscess/wound dehiscence (n = 3) and social issues (n = 2). The majority of patients (n = 105; 89 %) commenced postoperative chemotherapy within the intended time frame of 8 weeks following surgery. Four patients (3.4 %) were unable to receive chemotherapy within this period due to death (n = 2) or surgical morbidity (n = 2). In 7 (6 %) patients chemotherapy was not deemed necessary due to low grade histology or complete removal of the tumor at relapse. Two patients (1.7 %) refused chemotherapy. Median time between surgery and first cycle of postoperative chemotherapy was 37 days (range 13-101).
ICU data
Seventy-three patients (61.8 %) had a planned admission to the ICU for postoperative care with a median ICU stay of 1.7 days (range 0.6-104). The median fluid balance at the beginning of the first postoperative day was ?2200 ml (range -300 ml to ?6700 ml), although this was difficult to measure accurately in patients with significant ascites. Median fresh frozen plasma use was 0.27 units (range 0-4 units) and was given intraoperatively and within the first 48 h postoperatively. Ten of the 73 patients required packed red cells in the first 24 h postoperatively, receiving a median of median 2 units (range 1-4 units). The median albumin level pre-operatively was 34.0 g/l; range 9.0-40.5 g/l. Following surgery, the median albumin fell to 16 g/l (range 4.0-32.0 g/l). Three patients required temporary total parenteral nutrition (TPN) postoperatively. Forty patients received albumin supplementation in the presence of large volume ascites or pleural effusion and postoperative albumin levels of \20 g/l.
Survival data
Four patients (3.4 %) died within 3 months of surgery due to postsurgical organ failure (n = 2) or massive disease progression with liver and lung metastases (n = 2). All patients were at the initial presentation of their disease. Within a median follow-up period of 7 months (range 0-23), 30 (25 %) patients relapsed and 14 patients (11.9 %) died. Even though the survival data are still immature, median progression-free survival (PFS) was 15 months (95 % CI 11.94-18.06), while the median overall survival (OS) had not been reached. If we distinct patients to primary versus relapsed, then median PFS was 14 months for primary patients (95 % CI 1.28-11.49) and 18 months for relapsed patients. Of the 75 patients who completed their postoperative chemotherapy within the follow-up period, 27 (22.9 %) relapsed, of which 16 (13.5 %) occurred within a platinum resistant time window of 6 months. Median CA125 levels after completion of postoperative chemotherapy was 17 U/l (range 3-569).
Discussion
This case series represents the first UK-based analysis following introduction of the NICE (National Institute for Health and Care Excellence) guidance for ultraradical surgery in advanced EOC [15] , evaluating the surgical and anesthetic morbidity and mortality of extensive cytoreductive procedures. We believe we have shown the feasibility of this approach in the UK environment. We have demonstrated that when this type of surgery is performed within a specialized setting with appropriate infrastructure and maximal institutional effort, surgical morbidity and mortality appear acceptably low in the presence of high multivisceral resections and total macroscopic clearance scores. Despite the high rate of bowel resections, bowelrelated morbidity such as anastomotic leak was low, with comparably low rates of stoma formation. Importantly, only a small proportion of patients failed to proceed to systemic adjuvant treatment within the intended time window. The majority of the major morbidity incidents were identified early and managed successfully, through proactive and intensified multidisciplinary postoperative care. The median hospital stay of 8 days may seem long in the current fast track era. However, all patients included in the present analysis had extensive tumor burden, experienced large fluid shifts exacerbated by low albumin levels and underwent multivisceral resections. Also the median PFS of 15 months is perhaps lower than expected for a complete resection rate of more than 80 %; however, we have to consider the fact that in this analysis only high tumor burden patients were included and as we know from large scale studies, initial disease burden remains a significant unfavorable prognostic indicator despite complete tumor resection [31] .
The results from this series are encouraging and correlate well with similar European and American analyses in advanced EOC. Chi et al. describes a 22 % major morbidity rate in 141 patients who underwent extensive upper abdominal surgical procedures, with a mortality rate of 1.4 % [16] . The Mayo clinic experience on extensive cytoreductive surgery showed also a 20 % major morbidity and 6 % 3-month mortality rate [8] . Our results also correlate with the experience of other authors regarding the relatively low bowel-related morbidity [17] [18] [19] [20] without the necessity of high rates of a protective stoma. The Italian Gynecological Oncology Group describe an anastomotic leak rate of 1 %, abscess formation rate of 1 %, postoperative hemorrhage of 0.5 % and sepsis 2.7 % [20] . Other authors report similar anastomotic leak rates ranging between 1 and 3 %; bowel fistula/perforation rates between 1 and 5.4 % and sepsis 2.7-3.6 % [17] [18] [19] [20] [21] . The reason that the leak rates appear lower than the ones described for colorectal patients, is probably attributed to the fact that, as opposed to rectal cancer patients, EOC patients will rarely present with true tumor invasion into the lumen of the rectum at short distance to the anal verge, so that after extraperitoneal dissection and en bloc tumor resection, the colorectal anastomosis is usually at least 7-10 cm from the anal verge. This is known to be associated with a significantly lower anastomotic leak risk compared to lower anastomoses required for rectal cancer patients and usually safe enough to avoid the routine use of a protective ileostomy [19] .
One of the arguments made against extensive cytoreductive surgery is the notion of increased surgical morbidity and mortality in comparison to less radical surgery.
The largest UK-based analysis for debulking surgery in EOC, the recently published CHORUS trial [22] , showed an overall 28-day surgical mortality of 3 and 5.6 % in the primary cytoreductive arm. This was despite a much less radical approach where complete cytoreduction rate was 27 %, a bowel resection rate of 10 %, less than 30 % having undergone any other than the ''standard'' procedures and 12 % of patients not being stage IIIC/IV.
A further important consideration in the present analysis is the importance of adequate intra-and early postoperative fluid management. In a similar fashion to other European experiences, we have shown that fluid management is one of the greatest challenges in patients undergoing extensive cytoreductive surgery. Although blood loss does not appear to represent a significant problem [23, 24] , these patients require large volumes of fluid to correct pre-and perioperative fluid deficits from intraoperative loss of ascites and pleural effusions as well as insensible losses, and to compensate for cytokine release during peritonectomy [23] . Hypoalbuminemia is a predictor of increased morbidity and mortality in surgical or ICU patients [25, 26] , and therefore albumin was usually replaced in these patients using human albumin solution, even though no randomized trials exist to support this practice [27] .
Barton et al. emphasized that this type of surgery has implications for the centralization of surgical services and subspecialty training [6] . Although this may be provided in different models of health care, provision is probably best achieved by greater centralization of surgery to centers able to achieve high complete cytoreduction rates, and a system that supports the longer operative times required by this approach [6, 28] .
This problem of limited resources and compromising of surgical care expands beyond the borders of surgery for EOC. According to a major new Commission examining the state of global cancer surgery, over 80 % of the 15 million people diagnosed with cancer worldwide in 2015 will need surgery, but less than one-quarter of them will have access to proper, safe, affordable surgical care when they need it [29, 30] . New estimates suggest that less than 5 % of the patients in low-income countries and only roughly 22 % of the patients in middle-income countries can access even the even most basic cancer surgery. Despite this worldwide shortfall in access to cancer surgery, the international community does not see surgical care as an essential component of global cancer control, with surgical services being given low priority within national cancer plans and being allocated few resources, due to the many competing health priorities and substantial financial constraints [29, 30] . These findings make apparent that a rethinking needs to happen in terms of resource allocation, investment in surgical training and the overall philosophy of cancer services, especially in an upcoming era where increasingly more financial resources are allocated to novel systemic targeted agents and where progress and ''effort'' of systemic treatment should ideally be in line and meet surgical effort.
A significant limitation of the present analysis is the lack of quality of life data; however, a newly upcoming prospective quality of life evaluation study, the SOCQER-2 study (ClinicalTrials.gov Identifier: NCT02569983), will assess quality of life survey before and after radical surgery for advanced EOC.
Despite the considerable logistical and financial challenges involved in conducting randomized multicentre surgical trials, there has never been a more active and fruitful time for this than the present time. Numerous international consortia are currently focusing on answering many vital surgical questions such as the appropriate selection of patients, the optimum timing of surgery, the optimal allocation of resources, as well as the systematic evaluation of the postoperative quality of life, to finally establish and define surgical treatment of advanced EOC.
Concluding, we show that maximal effort cytoreductive surgery for EOC is feasible within a UK setting with acceptable morbidity, low intestinal stoma rates and without clinically relevant delays to postoperative chemotherapy. Careful patient selection, and coordinated multidisciplinary effort appear to be the key for good outcome. Future evaluations should include quality of life analyses.
